▲ 3.05%
prev close
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
Congressional Trades
1
All tracked trades
Members Trading
1
Unique members
Net Activity
-1
0 buys · 1 sells
Members Who Traded This Stock
1 trade events
| Date | Member | Stock | Type | Amount | Filed | Signal |
|---|---|---|---|---|---|---|
| 2023-03-06 | BMRNBioMarin Pharmaceutical Inc. | Sell | $1,001 - $15,000 | 1282d ago | — |
2023-03-06
Daniel Goldman
BMRN
Amount
$1,001 - $15,000
Filed
1282d ago
Recent News
Powered by Polygon.io
BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: Should You Buy?
FDA Grants Priority Review to BridgeBio's Dwarfism Drug Filing
Enzyme Replacement Therapy Market to Grow to USD 27.90 Billion by 2035 at a CAGR of 8.59% - SNS Insider
BioMarin Stops Voxzogo Development for Noonan Syndrome
How BioMarin Turned a Competitive Threat Into a Royalty-Bearing Asset
Trade Timeline
Congressional activity, newest first
Daniel Goldman
2023-03-06 · Sale
$1,001 - $15,000